Society of Urologic Oncology (SUO) 21st Annual Meeting

SUO 2020: Clinical Trials of Focal Prostate Ablation

( Dr. Ardeshir Rastinehad gave a summarized overview of the ongoing clinical trial of focal therapy in prostate cancer.

There are several types of ablative therapies that can be used for prostate cancer focal ablation. These include heat modalities:
  • High intensity focused ultrasound (HIFU)
  • Laser interstitial thermal therapy
  • High-pressure steam
  • Gold nanoparticle directed therapy
  • Microwave ablation
Cold modalities – Cryotherapy

And additional modalities:
  • Irreversible electroporation
  • Vascular targeted phototherapy
The evolving modality of gold nanoshell-localized photothermal ablation has been recently described and published.1

Figure 1 demonstrates the pre-and post-treatment MRIs of lesions treated with the gold nanoshell modality.

Figure 1 – Pre- and post MRI images of prostate tumors treated with gold nanoshell modalities:1


The three-month biopsy following treatment showed 74% (12/16) clinical success with a median prostate-specific antigen (PSA) reduction of 42%. The 12-month biopsy following treatment showed clinical success in 87.5% (14/16) of targeted biopsies. There were no major side effects or complications.

Another multicenter trial involving 44 men with a total of 45 lesions treated with the gold nanoshell modality was recently presented in the “FOCAL2020” meeting. PSA decreased at 12 months was shown in 48% of cases, and 32 lesions (71.1%) were biopsy negative following treatment.

Another emerging modality is MAGFORCE, which is a nanoparticle covered in iron oxide injected into the tumor. It is later exposed to an alternating magnetic field (100 kHz), generating field strength between 4 and 15 kA/m. The magnetic fluid, NanoTherm®, vibrates to therapeutic treatment temperatures in the tumor.

Concluding his talk, Dr. Rastinehad stated that he believes that focal therapy is a growing modality, and in the future, its role might be incorporated to treat more aggressive disease.

Presented by: Ardeshir R. Rastinehad, DO, Mount Sinai Urology, New-York, NY

Written by: Hanan Goldberg, MD, MSc, Assistant Professor, Urology Department, SUNY Upstate Medical University, Syracuse, NY, USA @GoldbergHanan at the 2020 Society of Urologic Oncology Annual Meeting – December 2-5, 2020 – Washington, DC


  1. Rastinehad AR, Anastos H, Wajswol E, et al. Gold nanoshell-localized photothermal ablation of prostate tumors in a clinical pilot device study. Proceedings of the National Academy of Sciences 2019; 116(37): 18590-6.